CN115386625A - Method for customizing skin care product based on light and dirt resistance genes and skin care product - Google Patents
Method for customizing skin care product based on light and dirt resistance genes and skin care product Download PDFInfo
- Publication number
- CN115386625A CN115386625A CN202210994706.9A CN202210994706A CN115386625A CN 115386625 A CN115386625 A CN 115386625A CN 202210994706 A CN202210994706 A CN 202210994706A CN 115386625 A CN115386625 A CN 115386625A
- Authority
- CN
- China
- Prior art keywords
- skin
- skin care
- care product
- oligopeptide
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 59
- 238000000034 method Methods 0.000 title claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 230000008099 melanin synthesis Effects 0.000 claims description 13
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 10
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 229960003121 arginine Drugs 0.000 claims description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 9
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000003344 environmental pollutant Substances 0.000 claims description 9
- 239000004519 grease Substances 0.000 claims description 9
- 231100000719 pollutant Toxicity 0.000 claims description 9
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- 102000006822 Agouti Signaling Protein Human genes 0.000 claims description 7
- 108010072151 Agouti Signaling Protein Proteins 0.000 claims description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- 108010077895 Sarcosine Proteins 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- 230000006750 UV protection Effects 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002738 chelating agent Substances 0.000 claims description 7
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 7
- 235000013922 glutamic acid Nutrition 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 229960002591 hydroxyproline Drugs 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- -1 polydimethylsiloxane Polymers 0.000 claims description 7
- 229940043230 sarcosine Drugs 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000002562 thickening agent Substances 0.000 claims description 7
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 6
- 229920002498 Beta-glucan Polymers 0.000 claims description 6
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 102100030943 Glutathione S-transferase P Human genes 0.000 claims description 5
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 claims description 5
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 claims description 5
- 102100037258 Membrane-associated transporter protein Human genes 0.000 claims description 5
- 108091007563 SLC45A2 Proteins 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- 241001506047 Tremella Species 0.000 claims description 5
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 5
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 5
- 230000004888 barrier function Effects 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 230000004060 metabolic process Effects 0.000 claims description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- 229940057910 shea butter Drugs 0.000 claims description 5
- 230000008591 skin barrier function Effects 0.000 claims description 5
- 229940032094 squalane Drugs 0.000 claims description 5
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 4
- 108010087806 Carnosine Proteins 0.000 claims description 4
- 102100025403 Epoxide hydrolase 1 Human genes 0.000 claims description 4
- 101001077852 Homo sapiens Epoxide hydrolase 1 Proteins 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 4
- 229960005305 adenosine Drugs 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 229940044199 carnosine Drugs 0.000 claims description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 4
- 229940119170 jojoba wax Drugs 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 4
- 235000008160 pyridoxine Nutrition 0.000 claims description 4
- 239000011677 pyridoxine Substances 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 3
- SCVVSSZVLZQUDZ-UHFFFAOYSA-N 3-methyl-2,6-dihydro-1H-pyrimidine-2-carboxylic acid Chemical compound CN1C(NCC=C1)C(=O)O SCVVSSZVLZQUDZ-UHFFFAOYSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 3
- 101001052785 Homo sapiens Ficolin-1 Proteins 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 235000009582 asparagine Nutrition 0.000 claims description 3
- 229960001230 asparagine Drugs 0.000 claims description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 3
- 239000011666 cyanocobalamin Substances 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 229940093497 ergothioneine Drugs 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229960002442 glucosamine Drugs 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 230000001333 moisturizer Effects 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 229960003471 retinol Drugs 0.000 claims description 3
- 235000020944 retinol Nutrition 0.000 claims description 3
- 239000011607 retinol Substances 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 3
- 229960000401 tranexamic acid Drugs 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 claims description 2
- GFEYWOGCSROPRT-OBXVVNIGSA-N (2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 GFEYWOGCSROPRT-OBXVVNIGSA-N 0.000 claims description 2
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 2
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims description 2
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 claims description 2
- ITIMHIATVYROGF-XWUOBKMESA-N (3S)-3-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O ITIMHIATVYROGF-XWUOBKMESA-N 0.000 claims description 2
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 2
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims description 2
- 102100024508 Ficolin-1 Human genes 0.000 claims description 2
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 claims description 2
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 claims description 2
- 101000661570 Homo sapiens Syntaxin-binding protein 5-like Proteins 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 2
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- 108010047657 Phe-Val-Ala-Pro-Phe-Pro Proteins 0.000 claims description 2
- 102100038004 Syntaxin-binding protein 5-like Human genes 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 2
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 2
- 229940094978 bis-peg-18 methyl ether dimethyl silane Drugs 0.000 claims description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 2
- PEUSZTDUWXURQK-BZRHSMGTSA-N methyl (2s)-2-[[(2s)-2-[[(3s,4s)-4-[[(2s)-2-[[2-[[(2s)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-6-methylheptanoyl]amino]propanoyl]amino]-3-phenylpropanoate Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CC=CC=C1 PEUSZTDUWXURQK-BZRHSMGTSA-N 0.000 claims description 2
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 2
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 claims description 2
- 108010030856 phenylalanyl-glycyl-valyl-statyl-alanyl-phenylalanine methyl ester Proteins 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 claims description 2
- 229960002104 cyanocobalamin Drugs 0.000 claims 1
- 229940105990 diglycerin Drugs 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 229940094541 polyglycerin-10 Drugs 0.000 claims 1
- 229940099549 polyglycerin-3 Drugs 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 80
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 28
- 102000003425 Tyrosinase Human genes 0.000 abstract description 9
- 108060008724 Tyrosinase Proteins 0.000 abstract description 9
- 238000001514 detection method Methods 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000002773 nucleotide Substances 0.000 abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 abstract description 4
- 238000012163 sequencing technique Methods 0.000 abstract description 4
- 230000004913 activation Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000002068 genetic effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000002752 melanocyte Anatomy 0.000 abstract description 3
- 230000035790 physiological processes and functions Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000004224 protection Effects 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 238000012546 transfer Methods 0.000 abstract description 3
- 230000036548 skin texture Effects 0.000 abstract 2
- 206010051246 Photodermatosis Diseases 0.000 description 11
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 10
- 230000008845 photoaging Effects 0.000 description 10
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 6
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 230000005808 skin problem Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940113082 thymine Drugs 0.000 description 5
- 229940035893 uracil Drugs 0.000 description 5
- 229940075420 xanthine Drugs 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- 229920000289 Polyquaternium Polymers 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 101150104892 AHR gene Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 101150015860 MC1R gene Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 108010051081 dopachrome isomerase Proteins 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000009967 Erodium cicutarium Nutrition 0.000 description 1
- 101150005296 FCN1 gene Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102100036534 Glutathione S-transferase Mu 1 Human genes 0.000 description 1
- 102100038055 Glutathione S-transferase theta-1 Human genes 0.000 description 1
- 101001071694 Homo sapiens Glutathione S-transferase Mu 1 Proteins 0.000 description 1
- 101001032462 Homo sapiens Glutathione S-transferase theta-1 Proteins 0.000 description 1
- 101100150582 Homo sapiens STXBP5L gene Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091029795 Intergenic region Proteins 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000000728 Thymus Neoplasms Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000019000 darkening of skin Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102200068758 rs2228479 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 201000009377 thymus cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
- A61K8/894—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/49—Solubiliser, Solubilising system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a method for customizing a skin care product based on light and dirt resistance genes and the skin care product, wherein the method analyzes the Single Nucleotide Polymorphism (SNP) of a specific gene sequence through a gene sequencing technology, reads the genetic information of skin texture through an accurate gene locus, comprehensively analyzes the functional physiological state of the skin of a subject and the skin texture problem which possibly occurs under various factors, and can select the customized skin care product according to the detection result. The skin care product has the advantages of effectively enhancing cell protection, reducing the activation of tyrosinase, reducing the transportation of tyrosinase, reducing the production of melanin, inhibiting the transfer of melanin from melanocytes to horny layers, enhancing the skin resistance and promoting the repair of DNA.
Description
Technical Field
The invention relates to the technical field of skin care products, in particular to a method for customizing a skin care product based on light and dirt resistance genes and the skin care product.
Background
With the development of scientific technology, the whole-gene spectrogram of human has been obtained by sequencing. Numerous studies currently indicate that the state of human skin is closely related to genes. The genotype of a specific site (or single nucleotide polymorphism of gene, SNPs, or simply gene polymorphism) in these skin-related genes may largely affect the state of the skin, and different genotypes are key factors causing skin problems. People can find or predict the problems of the skin by detecting different genotypes, and the problems are used as guidance to select proper skin care products. Further studies have found that, in addition to genotype, the expression of proteins due to genotype is a key factor causing skin problems.
There are a large number of skin care and beauty products with different functions available on the market today. However, the skin of each individual has uniqueness, and how to select skin care products suitable for the individual is an important problem faced by people. The method generally selected by consumers at present is to adopt a selection-purchase-trial mode to verify whether the skin care product is suitable for the consumers, and in the process, the consumers not only waste a great deal of time and financial resources, but also can cause discomfort of the skin, such as allergy and the like. Therefore, how to select a skin care product suitable for individual consumers becomes an important problem to be solved urgently.
Skin aging mainly includes endogenous aging and exogenous aging. Extrinsic aging refers to aging caused by the influence of environmental factors, and is also called photoaging because it is mainly affected by Ultraviolet (UV) radiation. Both long-wave Ultraviolet (UVA) and medium-wave Ultraviolet (UVB) light can cause photoaging. UVB has long been considered to be the main spectrum responsible for photoaging, since its burning effect on skin is 1000 times stronger than UVA. However, recent studies have shown that UVA is the main spectrum responsible for skin photoaging.
The main clinical manifestations of skin photoaging are skin wrinkles, roughness, dryness, laxity, telangiectasia, increased fragility and pigmentation. Chronic sun exposure can affect various cellular and tissue structural changes in the skin, with the most characteristic change being a change in the dermal extracellular matrix components. The dermal extracellular matrix includes collagen fibers, elastic fibers, aminopolysaccharides and proteoglycans, etc., among which type I collagen is its main structural protein. In photoaging skin, type I and type III collagen fibers are reduced and disordered, and elastic fibers are denatured and thickened, aggregated into blocks, and aminopolysaccharide is cracked, so that the skin is loosened and wrinkles are generated.
Excess ozone in the air reduces the levels of vitamin C and vitamin E in the skin, resulting in increased lipid peroxidation; automobile exhaust and polycyclic aromatic hydrocarbons, increasing oxidative stress and cell damage; pollutants floating in the air easily enter pores, seriously destroy the renewal cycle and speed of the stratum corneum, and cause a series of skin problems, which are shown as follows: the blood capillaries are seriously dilated, obvious red blood filaments appear, the skin sensitivity is increased, anaphylactic reaction, dark skin color, dark spot color, increased fine lines and the like easily appear.
Disclosure of Invention
The invention provides a method for customizing a skin care product based on light-resistant and pollution-resistant genes and the skin care product, wherein the good light-resistant and pollution-resistant capabilities are determined by the ultraviolet ray existing in the nature resisted by a human body and the illumination skin injury caused by an artificial ultraviolet light source, the melanin generation inhibiting level of skin cells, the color spot resisting capability of the skin per se and the metabolism removing capability of endogenous and exogenous pollutants.
In order to achieve the purpose, the invention adopts the following technical scheme:
a method for customizing skin care products based on light and dirt resistance genes comprises the steps of collecting user cell samples, extracting DNA and detecting polymorphism of anti-aging related genes in the DNA, wherein the light and dirt resistance genes comprise ultraviolet resistance related genes, melanin synthesis inhibition related genes, stain resistance related genes, pollutant metabolism capability related genes and skin barrier capability related genes.
Preferably, the genes related to the ultraviolet resistance comprise XPD, ASIP and STXBP5L.
Preferably, the genes related to the melanin synthesis inhibiting ability include SLC45A2, DCT, MC1R, ASIP and TYR.
Preferably, the stain resistance-associated gene includes MC1R.
Preferably, the genes related to the metabolic capacity of the pollutants comprise EPHX1, GSTP1 and AHR.
Preferably, the gene related to skin barrier ability comprises FCN1.
The skin care product customized based on the light and stain resistant genes comprises, by weight, 5-10 parts of a moisturizing agent, 0.5-6 parts of grease, 0.1-5 parts of amino acid, 0.1-6 parts of polypeptide, 0.2-2 parts of a solubilizing agent, 0.1-1 part of a thickening agent, 0.5-5 parts of a skin conditioner, 0.1-0.2 part of a chelating agent and 70-90 parts of water.
Preferably, the moisturizer comprises sodium hyaluronate, hydrolyzed sodium hyaluronate, tremella polysaccharide, dendrobii polysaccharide, beta-glucan, trehalose, betaine, propylene glycol, butylene glycol, 1, 2-pentanediol, 1, 2-hexanediol, glycerol, diglycerol, polyglycerol-3, polyglycerol-10, glycerol polyether-26, and polyquaternium-51; the grease comprises one or more of squalane, polydimethylsiloxane, bis-PEG-18 methyl ether dimethylsilane, bis-PEG-15 methyl ether polydimethylsiloxane, olive oil, jojoba oil and shea butter; the amino acid comprises one or more of tyrosine, phenylalanine, cystine, cysteine, tryptophan, sarcosine, lysine, hydroxyproline, methionine, histidine, arginine, aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, isoleucine, leucine, asparagine, glutamine, glucosamine, sodium chondroitin sulfate, pyridoxine, biotin, taurine, retinol, folic acid, riboflavin, nicotinamide, cyanocobalamine; the polypeptide comprises one or a combination of more of oligopeptide-1, oligopeptide-2, oligopeptide-3, oligopeptide-4, oligopeptide-5, oligopeptide-6, carnosine, adenosine, tripeptide-1 copper, tripeptide-3, pentapeptide-1, pentapeptide-3, hexapeptide-1, hexapeptide-3, hexapeptide-5, hexapeptide-9, hexapeptide-11, nonapeptide-1, palmitoyl tripeptide-5, acetyl hexapeptide-8, glutathione, arginine/lysine polypeptide, palmitoyl tetrapeptide-7, acetyl tetrapeptide-2, palmitoyl pentapeptide-4 and yeast polypeptide.
Preferably, ergothioneine is selected to be added according to the ultraviolet resistance of users; 1-methylhydantoin-2-imide and saccharomycete polypeptide extract are selectively added according to the melanin synthesis inhibiting capability of a user; the nicotinamide and the tranexamic acid are selectively added according to the anti-stain capability of a user; selecting and adding the tetrahydro-methyl pyrimidine carboxylic acid according to the pollutant metabolic capacity of a user; the addition of polyquaternium-51 and beta-glucan is selected for the barrier capacity of the skin of the user.
The invention is based on the existing technology that the cell sample of a user is collected, DNA is extracted, and the polymorphism of the anti-aging related gene in the DNA is detected.
anti-UV capability, UV is the main cause of skin photoaging. Photoaged skin appears as rough, flabby, atrophic, deeper and thicker wrinkles, with irregular pigmentation visible. There are mainly two kinds of UVA and UVB, wherein UVA is an important band for skin tanning and photoaging.
The STXBP5L gene encodes a synaptotagmin 5 analog. Analysis of the GWAS big data shows that the GWAS has correlation with the photoaging resistance of skin.
The synthesis of melanin is inhibited, human skin color is related to the synthesis of melanin, and the content and distribution of melanin in skin are main factors for determining the skin color.
Multiple risk alleles in the gene, such as MC1R, SLC45A2, ASIP and TYR, are involved in the synthesis of melanin, which is classified as true black and brown, only occipital melanin can help the skin reduce the effects of photoaging. The MC1R gene encodes the melanocortin receptor 1, which is responsible for regulating the type of melanin synthesized. rs2228479 is located on the MC1R gene, and when the site is AA or GA, more pheomelanin and less eumelanin are produced, thereby resulting in weak anti-photoaging ability.
SLC45A2 encoded membrane transporter regulates the pH in melanosomes, thereby regulating tyrosinase activity, and highly expressed SLC45A2 produces more melanin.
High expression of the Agouti protein encoded by the ASIP can result in the conversion of tyrosine into pheomelanin, and low expression can result in the conversion of tyrosine into eumelanin, which is a main factor for darkening of skin color.
High expression of tyrosinase encoded by TYR results in more tyrosine, and high levels of tyrosine result in more melanin synthesis.
DCT-encoded dopachrome isomerase regulates tyrosinase activity, is a key rate-limiting enzyme for melanin synthesis, and high expression of the dopachrome isomerase can lead to more melanin synthesis.
The pollutant metabolism ability skin is the biggest organ of human body, is the first line of defense of human body to protect external pollution, and environmental pollution can influence the function of skin, destroys the skin barrier, lets the skin dewater, still increases colour spot and wrinkle through oxidative stress.
The EPHX1 related literature is Genetic polymorphism and benzazene metabolism in humankind exp pgsed to a wide Range of air concentrations, and the two SNP sites (rs 1051740 and rs 22234922) of EPHX1 are found to be related to pollutant metabolic capability by performing experiments and data analysis on 250 artificial samples exposed in a polluted environment and 156 control samples.
GSTP 1-related documents are Polymorphisms at GSTM1, GSTP1, GSTT1 Detoxification Genes Loci and Risk of Breast Cancer in Kazakhstan Population, and by comparative experiments on 181 thymus Cancer patients and 397 normal persons, it was found that 105lle/Val polymorphism and Detoxification ability of GSTP1 in Asia were related.
The AHR gene encodes a helix-loop-helix transcription factor. Research analysis by the great teachings of GWAS shows that the factor is related to the appearance of the crow's foot, and rs2066853 is located on the AHR gene. When the site is AA or GA, the site is more easily damaged by environmental factors such as chemical substances and the like, DNA damage is caused, and the risk of the appearance of the fishtail line is increased.
The barrier ability of the skin, the barrier function of the skin, mainly includes two aspects: on one hand, the loss of water, electrolytes and other substances in the body can be prevented; on the other hand, the invasion of harmful or unwanted substances from the outside can be prevented.
The gene FCN1 encodes a fibrin-derived protein, which is localized in the stratum corneum and helps the skin retain water and protect against harmful substances from the outside. The rs11103631 site is positioned in an intergenic region and can influence the function of the FCN1 gene, and the site is mutated by G- > A, so that the skin is thinner, the keratinocyte permeability is strong, the keratinocyte is easy to lose water, and the keratinocyte is easily damaged by external harmful substances.
The beneficial effects of the invention are: according to the invention, single Nucleotide Polymorphism (SNP) of a specific gene sequence is analyzed through a gene sequencing technology, skin genetic information is read through an accurate gene locus, the skin function physiological state of a subject and skin problems possibly occurring under various factors are comprehensively analyzed, and a customized skin care product can be selected according to a detection result. The skin care product has the advantages of effectively enhancing cell protection, reducing the activation of tyrosinase, reducing the transportation of tyrosinase, reducing the production of melanin, inhibiting the transfer of melanin from melanocytes to horny layer, enhancing the skin resistance and promoting the repair of DNA.
Detailed Description
The following description will be given with reference to the embodiments in order to explain the technical contents, the objects and the effects of the present invention in detail.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the following terms have their intended meanings unless specifically defined otherwise.
The invention relates to a method for detecting anti-light and anti-pollution related genes, which belongs to the prior art and comprises the steps of collecting a user cell sample, extracting DNA and detecting polymorphism of anti-aging related genes in the DNA.
Example 1
Example 1A 39-year-old volunteer 1 was subjected to gene testing and ultraviolet resistance.
According to the detection result, the skin care product with the following formula is prepared: wherein the total mass of the skin care product is 100Kg,
humectant: 0.2Kg of tremella polysaccharide, 0.2Kg of trehalose, 7Kg of glycerol and 3Kg of polyglycerol;
grease: olive oil 0.5Kg, shea butter 0.2Kg;
amino acids: 0.2Kg of tyrosine, 0.2Kg of phenylalanine, 0.2Kg of tryptophan, 0.2Kg of sarcosine, 0.2Kg of lysine, 0.2Kg of hydroxyproline, 0.2Kg of histidine, 0.2Kg of arginine, 0.2Kg of aspartic acid, 0.2Kg of serine, 0.2Kg of glutamic acid, 0.2Kg of proline, 0.2Kg of glycine, 0.2Kg of alanine, 0.2Kg of valine, 0.2Kg of isoleucine, 0.2Kg of leucine, 0.2Kg of glucosamine, 0.2Kg of pyridoxine, 0.2Kg of biotin;
polypeptide: oligopeptide-1.2Kg, oligopeptide-2.2Kg, oligopeptide-3.2Kg, hexapeptide-11.2Kg, palmitoyl tripeptide-1.2Kg, acetyl hexapeptide-8.2Kg;
solubilizer: 1Kg of polyglycerol-10 laurate;
thickening agent: 0.5Kg of polyacrylate;
skin conditioner: 0.2Kg of uracil, 0.2Kg of xanthine, 0.2Kg of thymine and 0.2Kg of ergothioneine;
chelating agent: 0.1Kg of EDTA disodium; and others: the balance of water.
Example 2
In example 2, the ability to inhibit melanin synthesis was tested on volunteer 2 aged 40.
Preparing the following skin care product according to the detection result: wherein the total mass of the skin care product is 100Kg,
humectant: 0.2Kg of sodium hyaluronate, 2Kg of betaine, 5Kg of glycerin and-51 Kg of polyquaternium;
grease: 2Kg of bis-PEG-15 methyl ether polydimethylsiloxane and 2Kg of jojoba oil;
amino acids: 0.2Kg of tyrosine, 0.2Kg of phenylalanine, 0.2Kg of tryptophan, 0.2Kg of sarcosine, 0.2Kg of lysine, 0.2Kg of hydroxyproline, 0.2Kg of histidine, 0.2Kg of arginine, 0.2Kg of aspartic acid, 0.2Kg of threonine, 0.2Kg of serine, 0.2Kg of glutamic acid, 0.2Kg of proline, 0.2Kg of glycine, 0.2Kg of alanine, 0.2Kg of valine, 0.2Kg of isoleucine and 0.2Kg of leucine;
polypeptide: oligopeptide-1.2Kg, oligopeptide-2.2Kg, oligopeptide-3.2Kg, carnosine 0.2Kg, adenosine 0.2Kg, hexapeptide-110.2 Kg, nonapeptide-1.2Kg, yeast extract 0.2Kg;
solubilizer: 2Kg of PEG-60 hydrogenated castor oil;
thickening agent: 0.2Kg of polyacrylate;
skin conditioner: 0.2Kg of uracil, 0.2Kg of xanthine, 0.2Kg of thymine and 4Kg of 1-methylhydantoin-2-imide;
chelating agent: 0.2Kg of EDTA disodium; and others: the balance of water.
Example 3
The embodiment 3 of the invention aims at the 41-year-old volunteer 3 to carry out gene detection and has the capability of resisting color spots.
According to the detection result, the skin care product with the following formula is prepared: wherein the total mass of the skin care product is 100Kg,
humectant: 0.2Kg of tremella polysaccharide, 5Kg of propylene glycol and 3Kg of 1, 2-pentanediol;
grease: 1Kg of squalane and 0.5Kg of shea butter;
amino acids: 0.05Kg of tyrosine, 0.05Kg of phenylalanine, 0.05Kg of tryptophan, 0.05Kg of sarcosine, 0.05Kg of lysine, 0.05Kg of hydroxyproline, 0.05Kg of histidine, 0.05Kg of arginine, 0.05Kg of aspartic acid, 0.05Kg of serine, 0.05Kg of glutamic acid, 0.05Kg of proline, 0.05Kg of glycine, 0.05Kg of alanine, 0.05Kg of valine, 0.05Kg of isoleucine, 0.05Kg of leucine, 4Kg of nicotinamide;
polypeptide: oligopeptide-1.5Kg, oligopeptide-2.5Kg, oligopeptide-3.5Kg, hexapeptide-11.5Kg, nonapeptide-1.5Kg, yeast extract 0.5Kg;
solubilizer: 1Kg of PEG-60 hydrogenated castor oil;
thickening agent: 0.2Kg of polyacrylate;
skin conditioner: 0.05Kg of uracil, 0.05Kg of xanthine, 0.05Kg of thymine and 4.85Kg of tranexamic acid;
chelating agent: 0.1Kg of EDTA disodium; and others: the balance of water.
Example 4
Example 4 of the present invention was conducted on the gene testing and contaminant metabolizing ability of volunteer 4 aged 45 years.
According to the detection result, the skin care product with the following formula is prepared: wherein the total mass of the skin care product is 100Kg,
humectant: 0.5Kg of sodium hyaluronate, 0.5Kg of hydrolyzed sodium hyaluronate, 0.5Kg of beta-glucan, 26-5Kg of glyceryl polyether and 51.5Kg of polyquaternium;
grease: 1Kg of squalane and 1Kg of bis-PEG-18 dimethyl silane ether;
amino acids: 0.1Kg of tyrosine, 0.1Kg of phenylalanine, 0.05Kg of tryptophan, 0.05Kg of sarcosine, 0.05Kg of lysine, 0.1Kg of hydroxyproline, 0.05Kg of histidine, 0.05Kg of arginine, 0.05Kg of aspartic acid, 0.1Kg of threonine, 0.1Kg of serine, 0.05Kg of glutamic acid, 0.05Kg of proline, 0.1Kg of glycine, 0.05Kg of alanine, 0.05Kg of valine, 0.05Kg of isoleucine, 0.1Kg of leucine, 0.05Kg of asparagine, 0.05Kg of glutamine, 0.05Kg of pyridoxine, 0.05Kg of biotin;
polypeptide: oligopeptide-1.1Kg, oligopeptide-2.1Kg, oligopeptide-3.1Kg, carnosine 1Kg, adenosine 0.1Kg, hexapeptide-11.1Kg, nonapeptide-1.1Kg, glutathione 0.5Kg;
solubilizer: 20 Kg of polysorbate-20;
thickening agent: 0.3Kg of hydroxyethyl cellulose;
skin conditioner: 0.5Kg of uracil, 0.5Kg of xanthine, 0.5Kg of thymine, and 1Kg of tetrahydromethylpyrimidine carboxylic acid;
chelating agent: 0.2Kg of EDTA disodium; and others: the balance of water.
Example 5
Example 5 of the invention a gene test was performed on 47 years old volunteer 5, the barrier capacity of the skin.
According to the detection result, the skin care product with the following formula is prepared: wherein the total mass of the skin care product is 100Kg,
humectant: 0.5Kg of sodium hyaluronate, 0.5Kg of hydrolyzed sodium hyaluronate, 0.5Kg of tremella polysaccharide, 0.5Kg of dendrobe polysaccharide, 0.5Kg of beta-glucan, 5Kg of 1, 2-pentanediol, and-51 Kg of polyquaternium;
grease: 1Kg of squalane, 2Kg of olive oil, 2Kg of jojoba oil and 1Kg of shea butter;
amino acid (b): 0.1Kg of tyrosine, 0.1Kg of phenylalanine, 0.1Kg of cystine, 0.1Kg of cysteine, 0.1Kg of tryptophan, 0.1Kg of sarcosine, 0.1Kg of lysine, 0.1Kg of hydroxyproline, 0.1Kg of methionine, 0.1Kg of histidine, 0.1Kg of arginine, 0.1Kg of aspartic acid, 0.1Kg of threonine, 0.1Kg of serine, 0.1Kg of glutamic acid, 0.1Kg of proline, 0.1Kg of glycine, 0.1Kg of alanine, 0.1Kg of valine, 0.1Kg of isoleucine, 0.1Kg of leucine, 0.1Kg of retinol, 0.1Kg of folic acid, 0.1Kg of riboflavin, 0.1Kg of cyanocobalamine;
polypeptide: oligopeptide-1.1Kg, oligopeptide-2.1Kg, oligopeptide-3.1Kg, tripeptide-1 copper 0.1Kg, hexapeptide-11.1Kg, arginine/lysine polypeptide 0.1Kg, palmitoyl tetrapeptide-7.1Kg;
solubilizer: 1Kg of PEG-40 hydrogenated castor oil and 1Kg of polyglycerol-10 laurate;
thickening agent: 0.3Kg of hydroxypropyl guar gum;
skin conditioner: 0.5Kg of uracil, 0.5Kg of xanthine and 0.5Kg of thymine;
chelating agent: 0.1Kg of EDTA disodium; and others: the balance of water.
Melanin testing was performed on the users of examples 1-5 and data was recorded for 2 weeks, 4 weeks, 6 weeks and 8 weeks of use, as shown in table 1 below.
TABLE 1 test results
| Melanin pigment | Before use | 2w | 4w | 6w | 8w |
| Example 1 | 205.6 | 161.8 | 160.4 | 160.2 | 157.8 |
| Example 2 | 105.4 | 102.4 | 100 | 89.8 | 80.6 |
| Example 3 | 140.8 | 133.2 | 127.4 | 135 | 123.8 |
| Example 4 | 106.4 | 93.2 | 104 | 98.6 | 85 |
| Example 5 | 122.4 | 109.4 | 114.5 | 117.8 | 114.4 |
As can be seen from Table 1, the melanin levels in the skin care products of examples 1-5 were all somewhat reduced within 8 weeks of use of the customized skin care products of the present invention.
The invention analyzes the Single Nucleotide Polymorphism (SNP) of a specific gene sequence by a gene sequencing technology, reads the skin genetic information by accurate gene loci, comprehensively analyzes the skin functional physiological state of a subject and skin problems possibly appearing under various factors, and can select a customized skin care product according to the detection result. The skin care product has the advantages of effectively enhancing cell protection, reducing the activation of tyrosinase, reducing the transportation of tyrosinase, reducing the production of melanin, inhibiting the transfer of melanin from melanocytes to horny layers, enhancing the skin resistance and promoting the repair of DNA.
It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the appended claims.
Claims (9)
1. A method for customizing skin care products based on light and dirt resistance genes comprises the steps of collecting user cell samples, extracting DNA and detecting polymorphism of anti-aging related genes in the DNA, and is characterized in that the light and dirt resistance genes comprise ultraviolet resistance related genes, melanin synthesis inhibition related genes, stain resistance related genes, pollutant metabolism resistance related genes and skin barrier capacity related genes.
2. The method of claim 1, wherein the genes associated with UV resistance include XPD, ASIP and STXBP5L.
3. The method of claim 1, wherein the genes involved in the melanin synthesis inhibition comprise SLC45A2, DCT, MC1R, ASIP and TYR.
4. The method of claim 1, wherein the gene associated with stain resistance comprises MC1R.
5. The method of claim 1, wherein the genes associated with metabolic capacity of contaminants include EPHX1, GSTP1 and AHR.
6. The method of claim 1, wherein the gene associated with skin barrier ability comprises FCN1.
7. The skin care product customized based on the light and stain resistant gene as claimed in claim 1, wherein the raw materials of the skin care product comprise, by weight, 5-10 parts of moisturizer, 0.5-6 parts of grease, 0.1-5 parts of amino acid, 0.1-6 parts of polypeptide, 0.2-2 parts of solubilizer, 0.1-1 part of thickener, 0.5-5 parts of skin conditioner, 0.1-0.2 part of chelating agent and 70-90 parts of water.
8. The skin care product customized based on the light and stain resistance gene of claim 7, wherein the moisturizer comprises sodium hyaluronate, hydrolyzed sodium hyaluronate, tremella polysaccharide, dendrobii polysaccharide, beta-glucan, trehalose, betaine, propylene glycol, butylene glycol, 1, 2-pentanediol, 1, 2-hexanediol, glycerin, diglycerin, polyglycerin-3, polyglycerin-10, glyceryl polyether-26, polyquaternium-51; the grease comprises one or more of squalane, polydimethylsiloxane, bis-PEG-18 methyl ether dimethylsilane, bis-PEG-15 methyl ether polydimethylsiloxane, olive oil, jojoba oil and shea butter; the amino acids include one or more of tyrosine, phenylalanine, cystine, cysteine, tryptophan, sarcosine, lysine, hydroxyproline, methionine, histidine, arginine, aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, valine, isoleucine, leucine, asparagine, glutamine, glucosamine, sodium chondroitin sulfate, pyridoxine, biotin, taurine, retinol, folic acid, riboflavin, nicotinamide, cyanocobalamin; the polypeptide comprises one or a combination of more of oligopeptide-1, oligopeptide-2, oligopeptide-3, oligopeptide-4, oligopeptide-5, oligopeptide-6, carnosine, adenosine, tripeptide-1 copper, tripeptide-3, pentapeptide-1, pentapeptide-3, hexapeptide-1, hexapeptide-3, hexapeptide-5, hexapeptide-9, hexapeptide-11, nonapeptide-1, palmitoyl tripeptide-5, acetyl hexapeptide-8, glutathione, arginine/lysine polypeptide, palmitoyl tetrapeptide-7, acetyl tetrapeptide-2, palmitoyl pentapeptide-4 and yeast polypeptide.
9. The skin care product customized based on light and dirt resistance gene according to claim 8, wherein ergothioneine is selectively added according to the ultraviolet resistance of a user; 1-methylhydantoin-2-imide and yeast polypeptide extract are selectively added according to the melanin synthesis inhibiting capability of a user; the nicotinamide and the tranexamic acid are selectively added according to the anti-stain capability of a user; selecting and adding the tetrahydro-methyl pyrimidine carboxylic acid according to the pollutant metabolic capacity of a user; the polyquaternium-51 and beta-glucan are chosen to be added to the barrier capacity of the skin of the user.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210994706.9A CN115386625A (en) | 2022-08-18 | 2022-08-18 | Method for customizing skin care product based on light and dirt resistance genes and skin care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210994706.9A CN115386625A (en) | 2022-08-18 | 2022-08-18 | Method for customizing skin care product based on light and dirt resistance genes and skin care product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115386625A true CN115386625A (en) | 2022-11-25 |
Family
ID=84121237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210994706.9A Pending CN115386625A (en) | 2022-08-18 | 2022-08-18 | Method for customizing skin care product based on light and dirt resistance genes and skin care product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115386625A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116831939A (en) * | 2023-08-04 | 2023-10-03 | 广东暨大基因药物工程研究中心有限公司 | Glutathione synergistic four-component whitening composition and application thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008056569A (en) * | 2006-08-29 | 2008-03-13 | Fujifilm Corp | External preparation for skin |
| WO2011126163A1 (en) * | 2010-04-08 | 2011-10-13 | 주식회사 웰스킨 | Skin-whitening composition containing dipeptide |
| CN106755390A (en) * | 2016-12-15 | 2017-05-31 | 上海东方杰玛基因生物科技有限公司 | A kind of Primer composition and detection method for skin anti-aging ability genetic test |
| CN107828860A (en) * | 2017-12-12 | 2018-03-23 | 杜立波 | A kind of skin care item method for customizing based on genetic test |
| CN108004328A (en) * | 2017-12-12 | 2018-05-08 | 杜立波 | A kind of Skin whitening care cosmetics method for customizing |
| CN108004329A (en) * | 2017-12-12 | 2018-05-08 | 杜立波 | A kind of skin care item method for customizing for improving allergy skin quality |
| CN108542831A (en) * | 2018-07-05 | 2018-09-18 | 上海新高姿化妆品有限公司 | A kind of whitening and skin-protecting water and preparation method thereof with collaboration whitening effect |
| CN110478264A (en) * | 2019-09-29 | 2019-11-22 | 上海克琴科技有限公司 | A kind of cosmetic or skin composition with delay skin aging effect |
| CN110904207A (en) * | 2019-06-14 | 2020-03-24 | 陕西九州医学检验有限公司 | Susceptible gene detection panel related to skin aging characterization and application thereof |
| CN113314186A (en) * | 2021-07-06 | 2021-08-27 | 广州润孚创新科技有限公司 | Skin aging gene information detection and deep clinical analysis method |
-
2022
- 2022-08-18 CN CN202210994706.9A patent/CN115386625A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008056569A (en) * | 2006-08-29 | 2008-03-13 | Fujifilm Corp | External preparation for skin |
| WO2011126163A1 (en) * | 2010-04-08 | 2011-10-13 | 주식회사 웰스킨 | Skin-whitening composition containing dipeptide |
| CN106755390A (en) * | 2016-12-15 | 2017-05-31 | 上海东方杰玛基因生物科技有限公司 | A kind of Primer composition and detection method for skin anti-aging ability genetic test |
| CN107828860A (en) * | 2017-12-12 | 2018-03-23 | 杜立波 | A kind of skin care item method for customizing based on genetic test |
| CN108004328A (en) * | 2017-12-12 | 2018-05-08 | 杜立波 | A kind of Skin whitening care cosmetics method for customizing |
| CN108004329A (en) * | 2017-12-12 | 2018-05-08 | 杜立波 | A kind of skin care item method for customizing for improving allergy skin quality |
| CN108542831A (en) * | 2018-07-05 | 2018-09-18 | 上海新高姿化妆品有限公司 | A kind of whitening and skin-protecting water and preparation method thereof with collaboration whitening effect |
| CN110904207A (en) * | 2019-06-14 | 2020-03-24 | 陕西九州医学检验有限公司 | Susceptible gene detection panel related to skin aging characterization and application thereof |
| CN110478264A (en) * | 2019-09-29 | 2019-11-22 | 上海克琴科技有限公司 | A kind of cosmetic or skin composition with delay skin aging effect |
| CN113314186A (en) * | 2021-07-06 | 2021-08-27 | 广州润孚创新科技有限公司 | Skin aging gene information detection and deep clinical analysis method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116831939A (en) * | 2023-08-04 | 2023-10-03 | 广东暨大基因药物工程研究中心有限公司 | Glutathione synergistic four-component whitening composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10512603B2 (en) | Ferment extract of Eupenicillium crustaceum and cosmetic use thereof | |
| US8674072B2 (en) | Cosmetic and/or pharmaceutical composition comprising a peptidic hydrolyzate that can reinforce the barrier function | |
| CN108852894A (en) | It is a kind of for repairing the polypeptides in combination of whitening wrinkle-removing | |
| CN100592902C (en) | Applicaiton of paeoniflorin in preparation of composition for treating and preventing skin aging | |
| CN102439027B (en) | Peptide hydrolysate proteasome activators and compositions containing same | |
| CN111437237A (en) | Skin care composition with antioxidant, anti-saccharification and anti-aging effects and application thereof | |
| CN115386625A (en) | Method for customizing skin care product based on light and dirt resistance genes and skin care product | |
| CN110731919A (en) | Application of Mirabilis jalapa extracts and skin external preparation containing the same | |
| DE50016068D1 (en) | PEPTIDES FOR VACCINATING AGAINST THE HUMANE CMV | |
| AU2019388295A1 (en) | Polypeptides and methods for improving skin conditions | |
| CN110279599A (en) | A kind of lightening compositions, suit containing lightening compositions and preparation method thereof | |
| CN109125194B (en) | Air cushion foundation with blue light resisting effect and preparation method thereof | |
| KR20120020716A (en) | Cosmetic composition for improving skin elasticity | |
| Chan et al. | A coordinated approach to cutaneous wound healing: vibrational microscopy and molecular biology | |
| KR20190035444A (en) | An anti-aging functional cosmetic composition comprising an Undaria pinnatifida extract, an Ecklonia cava extract and glycosaminoglycan | |
| Hoppel et al. | The effect of a damaged skin barrier on percutaneous absorption of SDS and skin hydration investigated by confocal Raman spectroscopy. | |
| CN111732634B (en) | Application of earthworm active peptide for inhibiting melanocyte proliferation in preparation of medicines or cosmetics | |
| Rasmont et al. | Vichy volcanic mineralizing water has unique properties to strengthen the skin barrier and skin defenses against exposome aggressions | |
| EP3366694B1 (en) | Novel peptide and cosmetic composition comprising same for preventing skin aging or skin wrinkle formation | |
| CN114423400B (en) | Cosmetic composition containing graphene quantum dots as active ingredient | |
| KR102211099B1 (en) | A cosmetic composition for improving skin condition comprising functional lipopeptides | |
| CN110934772A (en) | Wrinkle-removing and anti-aging composition and application thereof in cosmetics | |
| CN110731918A (en) | Application of Nitraria tangutorum bobr extracts and skin external preparation containing same | |
| KR102260051B1 (en) | Cosmetic composition comprising graphene oxides | |
| WO2017074009A1 (en) | Antiaging cosmetic composition containing keratin peptides as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |